Cite
HARVARD Citation
Fehrenbacher, L. et al. (2016). Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 387 (10030), pp. 1837-1846. [Online].